NEW YORK (GenomeWeb News) – PerkinElmer has licensed photon detection technology developed by the Max Planck Institute for use in a range of molecular imaging applications, the Waltham, Mass.-based company said today.
Under the exclusive agreement with Max Planck Innovation, the Max Planck Institute's technology transfer arm, the company has licensed solid state silicon photomultiplier, or SiPM, technology that it will use in clinical diagnostics, as well as molecular detection and analytical applications, the company said.
The SiPM technology, which was developed by scientists at the Max Planck Institute for Physics and the Moscow State Engineering Physics Institute, offers high photon detection efficiencies, short response time, and low power consumption, which makes it useful in a range of low light level applications, the company said.
PerkinElmer's VP and GM of global detection, Michael Ersoni, said in a statement that the new technology "shows promise for several important human and environmental health applications."